S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:AEZS

Aeterna Zentaris Competitors

$0.39
-0.02 (-4.87 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.39
Now: $0.39
$0.41
50-Day Range
$0.30
MA: $0.35
$0.42
52-Week Range
$0.29
Now: $0.39
$1.54
Volume981,407 shs
Average Volume2.03 million shs
Market Capitalization$24.50 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05

Competitors

Aeterna Zentaris (NASDAQ:AEZS) Vs. SBPH, VRNA, CLSD, OBSV, KZIA, and ARAV

Should you be buying AEZS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aeterna Zentaris, including Spring Bank Pharmaceuticals (SBPH), Verona Pharma (VRNA), Clearside Biomedical (CLSD), ObsEva (OBSV), Kazia Therapeutics (KZIA), and Aravive (ARAV).

Spring Bank Pharmaceuticals (NASDAQ:SBPH) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Spring Bank Pharmaceuticals and Aeterna Zentaris' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spring Bank PharmaceuticalsN/AN/A$-24,100,000.00($1.47)-3.80
Aeterna Zentaris$530,000.0046.23$-6,040,000.00N/AN/A

Aeterna Zentaris has higher revenue and earnings than Spring Bank Pharmaceuticals.

Insider & Institutional Ownership

17.2% of Spring Bank Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. 12.7% of Spring Bank Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spring Bank Pharmaceuticals and Aeterna Zentaris' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spring Bank PharmaceuticalsN/A-89.89%-52.89%
Aeterna Zentaris-369.10%-125.54%-21.45%

Analyst Recommendations

This is a summary of current ratings for Spring Bank Pharmaceuticals and Aeterna Zentaris, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spring Bank Pharmaceuticals03102.25
Aeterna Zentaris0000N/A

Spring Bank Pharmaceuticals presently has a consensus price target of $1.7333, indicating a potential downside of 68.94%. Given Spring Bank Pharmaceuticals' higher possible upside, equities research analysts clearly believe Spring Bank Pharmaceuticals is more favorable than Aeterna Zentaris.

Risk & Volatility

Spring Bank Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Summary

Spring Bank Pharmaceuticals beats Aeterna Zentaris on 6 of the 11 factors compared between the two stocks.

Verona Pharma (NASDAQ:VRNA) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Verona Pharma and Aeterna Zentaris' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verona PharmaN/AN/A$-40,780,000.00($3.10)-2.34
Aeterna Zentaris$530,000.0046.23$-6,040,000.00N/AN/A

Aeterna Zentaris has higher revenue and earnings than Verona Pharma.

Insider & Institutional Ownership

54.5% of Verona Pharma shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Verona Pharma and Aeterna Zentaris' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verona PharmaN/A-115.93%-73.68%
Aeterna Zentaris-369.10%-125.54%-21.45%

Analyst Recommendations

This is a summary of current ratings for Verona Pharma and Aeterna Zentaris, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verona Pharma00403.00
Aeterna Zentaris0000N/A

Verona Pharma presently has a consensus price target of $22.75, indicating a potential upside of 213.36%. Given Verona Pharma's higher possible upside, equities research analysts clearly believe Verona Pharma is more favorable than Aeterna Zentaris.

Risk & Volatility

Verona Pharma has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Clearside Biomedical (NASDAQ:CLSD) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Clearside Biomedical and Aeterna Zentaris' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearside Biomedical$2.17 million43.67$-30,770,000.00($0.81)-2.42
Aeterna Zentaris$530,000.0046.23$-6,040,000.00N/AN/A

Aeterna Zentaris has lower revenue, but higher earnings than Clearside Biomedical.

Insider & Institutional Ownership

25.2% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. 13.1% of Clearside Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Clearside Biomedical and Aeterna Zentaris' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clearside Biomedical-144.47%-153.41%-65.29%
Aeterna Zentaris-369.10%-125.54%-21.45%

Analyst Recommendations

This is a summary of current ratings for Clearside Biomedical and Aeterna Zentaris, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clearside Biomedical02302.60
Aeterna Zentaris0000N/A

Clearside Biomedical presently has a consensus price target of $5.75, indicating a potential upside of 193.37%. Given Clearside Biomedical's higher possible upside, equities research analysts clearly believe Clearside Biomedical is more favorable than Aeterna Zentaris.

Risk & Volatility

Clearside Biomedical has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

ObsEva (NASDAQ:OBSV) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Insider & Institutional Ownership

48.5% of ObsEva shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for ObsEva and Aeterna Zentaris, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ObsEva11402.50
Aeterna Zentaris0000N/A

ObsEva presently has a consensus price target of $14.3333, indicating a potential upside of 635.04%. Given ObsEva's higher possible upside, equities research analysts clearly believe ObsEva is more favorable than Aeterna Zentaris.

Valuation and Earnings

This table compares ObsEva and Aeterna Zentaris' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ObsEvaN/AN/A$-108,790,000.00($2.49)-0.78
Aeterna Zentaris$530,000.0046.23$-6,040,000.00N/AN/A

Aeterna Zentaris has higher revenue and earnings than ObsEva.

Profitability

This table compares ObsEva and Aeterna Zentaris' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ObsEvaN/A-195.77%-86.73%
Aeterna Zentaris-369.10%-125.54%-21.45%

Risk & Volatility

ObsEva has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Aeterna Zentaris (NASDAQ:AEZS) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

2.1% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 11.9% of Kazia Therapeutics shares are owned by institutional investors. 1.0% of Kazia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aeterna Zentaris and Kazia Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeterna Zentaris0000N/A
Kazia Therapeutics0000N/A

Earnings and Valuation

This table compares Aeterna Zentaris and Kazia Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeterna Zentaris$530,000.0046.23$-6,040,000.00N/AN/A
Kazia Therapeutics$710,000.00131.24$-8,370,000.00($1.30)-7.58

Aeterna Zentaris has higher earnings, but lower revenue than Kazia Therapeutics.

Profitability

This table compares Aeterna Zentaris and Kazia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeterna Zentaris-369.10%-125.54%-21.45%
Kazia TherapeuticsN/AN/AN/A

Volatility and Risk

Aeterna Zentaris has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500.

Summary

Kazia Therapeutics beats Aeterna Zentaris on 8 of the 10 factors compared between the two stocks.

Aeterna Zentaris (NASDAQ:AEZS) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

2.1% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 51.2% of Aravive shares are owned by institutional investors. 30.5% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aeterna Zentaris and Aravive, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeterna Zentaris0000N/A
Aravive01602.86

Aravive has a consensus target price of $26.20, indicating a potential upside of 352.50%. Given Aravive's higher possible upside, analysts plainly believe Aravive is more favorable than Aeterna Zentaris.

Earnings and Valuation

This table compares Aeterna Zentaris and Aravive's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeterna Zentaris$530,000.0046.23$-6,040,000.00N/AN/A
Aravive$4.75 million19.61$-18,220,000.00($1.57)-3.69

Aeterna Zentaris has higher earnings, but lower revenue than Aravive.

Profitability

This table compares Aeterna Zentaris and Aravive's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeterna Zentaris-369.10%-125.54%-21.45%
AraviveN/A-47.21%-39.11%

Volatility and Risk

Aeterna Zentaris has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Aravive has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500.

Summary

Aravive beats Aeterna Zentaris on 8 of the 12 factors compared between the two stocks.


Aeterna Zentaris Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Spring Bank Pharmaceuticals logo
SBPH
Spring Bank Pharmaceuticals
0.8$5.58-3.0%$96.35 millionN/A-3.21
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.26-0.3%$95.59 millionN/A-2.21
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.5$1.96-15.3%$94.77 million$2.17 million-6.13Insider Buying
ObsEva logo
OBSV
ObsEva
1.4$1.95-1.0%$93.60 millionN/A-0.78Analyst Revision
KZIA
Kazia Therapeutics
0.4$9.85-5.1%$93.18 million$710,000.00-7.58
ARAV
Aravive
1.5$5.79-2.2%$93.14 million$4.75 million-2.82Analyst Downgrade
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.00-3.0%$93.11 million$61.30 million-2.21
Leap Therapeutics logo
LPTX
Leap Therapeutics
1.5$1.50-0.7%$89.49 millionN/A-1.13
NRBO
NeuroBo Pharmaceuticals
1.6$5.40-0.7%$88.71 millionN/A-1.32
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.5$0.55-1.8%$86.44 millionN/A-0.06
Eyenovia logo
EYEN
Eyenovia
1.5$3.45-1.4%$85.85 millionN/A-2.97
Synlogic logo
SYBX
Synlogic
1.6$2.45-11.4%$85.34 million$2.22 million-1.48Analyst Downgrade
High Trading Volume
Unusual Options Activity
Capricor Therapeutics logo
CAPR
Capricor Therapeutics
1.2$4.03-0.0%$82.41 million$1 million-3.77
Gemphire Therapeutics logo
GEMP
Gemphire Therapeutics
0.5$5.40-0.7%$80.31 millionN/A0.00
Evoke Pharma logo
EVOK
Evoke Pharma
1.4$3.02-1.0%$79.70 millionN/A-6.29
Galmed Pharmaceuticals logo
GLMD
Galmed Pharmaceuticals
1.5$3.77-1.3%$79.60 million$2.04 million-3.28Analyst Report
KemPharm logo
KMPH
KemPharm
1.6$1.10-1.8%$79.58 million$12.84 million-1.92
APM
Aptorum Group
0.5$2.33-3.0%$79.25 million$540,000.000.00Heavy News Reporting
MRKR
Marker Therapeutics
1.1$1.65-3.0%$79.24 million$210,000.00-3.24Analyst Report
Satsuma Pharmaceuticals logo
STSA
Satsuma Pharmaceuticals
1.4$4.54-1.5%$79.10 millionN/A-1.08
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$3.23-13.9%$75.99 million$2.70 million-9.79Earnings Announcement
High Trading Volume
SCYNEXIS logo
SCYX
SCYNEXIS
1.4$6.81-9.7%$74.50 million$120,000.00-1.38High Trading Volume
Immutep logo
IMMP
Immutep
1.3$1.87-2.1%$72.93 million$4.92 million0.00
ZOM
Zomedica
1.3$0.13-0.0%$70.73 millionN/A-1.25High Trading Volume
Savara logo
SVRA
Savara
1.6$1.29-7.0%$69.84 millionN/A-0.89Analyst Report
MITO
Stealth BioTherapeutics
1.3$1.32-0.0%$68.80 million$21.09 million33.01
AGE
AgeX Therapeutics
0.5$1.82-3.3%$68.59 million$1.73 million-6.07
Novan logo
NOVN
Novan
1.2$0.48-0.0%$67.22 million$4.90 million-2.16
Kitov Pharma logo
KTOV
Kitov Pharma
1.4$4.08-1.7%$64.16 million$1 million-1.36
ETTX
Entasis Therapeutics
1.8$1.77-0.6%$62.79 million$7 million-0.53High Trading Volume
Aridis Pharmaceuticals logo
ARDS
Aridis Pharmaceuticals
1.3$7.01-2.4%$62.55 million$1.02 million-2.83Earnings Announcement
Analyst Report
Analyst Revision
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.2$0.80-6.3%$62.16 millionN/A-1.66
Bellerophon Therapeutics logo
BLPH
Bellerophon Therapeutics
1.9$6.50-9.7%$61.74 millionN/A-1.96
Soligenix logo
SNGX
Soligenix
1.4$2.06-1.0%$61.49 million$4.60 million-2.94
ASLAN Pharmaceuticals logo
ASLN
ASLAN Pharmaceuticals
1.2$1.87-2.7%$59.93 million$3 million-1.73Analyst Upgrade
MREO
Mereo BioPharma Group
0.6$2.37-0.4%$59.01 millionN/A-0.95
TRVI
Trevi Therapeutics
1.6$3.09-1.0%$56.80 millionN/A-2.07
Recro Pharma logo
REPH
Recro Pharma
1.8$2.38-2.5%$56.28 million$99.22 million11.90
MNPR
Monopar Therapeutics
1.5$4.90-0.6%$56.12 millionN/A-10.89
Avenue Therapeutics logo
ATXI
Avenue Therapeutics
1.2$3.33-1.2%$55.77 millionN/A-5.12Upcoming Earnings
Proteostasis Therapeutics logo
PTI
Proteostasis Therapeutics
1.4$1.05-3.8%$54.79 million$5 million-1.25
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.5$0.95-5.3%$52.48 millionN/A0.00Heavy News Reporting
Vascular Biogenics logo
VBLT
Vascular Biogenics
1.3$1.24-2.4%$51.78 million$560,000.00-2.09
PLx Pharma logo
PLXP
PLx Pharma
0.9$5.60-0.9%$51.27 million$570,000.00-7.57Analyst Downgrade
High Trading Volume
Conatus Pharmaceuticals logo
CNAT
Conatus Pharmaceuticals
0.7$1.54-0.6%$51.08 million$21.72 million-5.13Heavy News Reporting
Merrimack Pharmaceuticals logo
MACK
Merrimack Pharmaceuticals
0.7$3.78-0.3%$50.58 millionN/A0.00
Daré Bioscience logo
DARE
Daré Bioscience
1.4$1.33-0.0%$50.53 millionN/A-1.48
EDSA
Edesa Biotech
0.7$5.30-1.1%$49.89 million$210,000.00-8.98
Diffusion Pharmaceuticals logo
DFFN
Diffusion Pharmaceuticals
1.4$0.78-10.3%$49.65 millionN/A-0.44
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.3$0.27-3.8%$49.20 million$2.18 million-0.18
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.